Drugs
Jun
Glyburide Shows Promise as a Treatment for Gestational Diabetes
The use of glyburide to treat gestational diabetes has become more frequent. Tempe A et al. conducted a prospective comparative study assessing the efficacy of glyburide to insulin in the treatment of gestational diabetes.
Jun
Investigation into safety of new diabetes drugs—will manufacturers release their data?
New forms of diabetes drugs, known as GLP-1-based drugs, and promoted as “the new darlings of diabetes treatment” make the pharmaceutical industry billions. But are they associated with an increased risk of cancer and do we know everything we should about these new treatments?
Jun
Daily Mail – TII diabetes drugs taken by thousands linked to cancer of the pancreas
They contain a man-made version of the hormone glucagon-like peptide 1 (GLP-1), which is produced by the intestines and prompts the body to release insulin – the chemical that controls blood sugar levels.
Jun
CNN: FDA panel urges looser restrictions on diabetes drug Avandia
Thirteen members voted to modify the current restrictions, while another seven voted to remove them altogether. Five members voted to continue the restrictions without changes, while one voted to remove Avandia from the market.
Jun
US panel wants changes to Avandia safety measures (Update)
US government health experts are recommending changes to safety restrictions on former blockbuster diabetes pill Avandia, in light of a new analysis suggesting that the drug may not increase the risk of heart attack as previously believed.
Jun
The Boston Globe – FDA to reexamine restrictions on diabetes drug
Three years ago the diabetes drug Avandia was all but banned from use in the United States after researchers found that thousands of people had heart problems after taking it. Today, it is a drug of last resort for people with diabetes who are so sick that a heart attack is worth the risk.
Jun
The NY Times: A Lone Voice Raises Alarms on Lucrative Diabetes Drugs
Based on his latest study, both the Food and Drug Administration and the European Medicines Agency have begun investigations that could lead to new warnings on the drugs, or even to their removal from the market.
Jun
DiabetesHealth: Ready for a Diabetes Drug Tune-Up?
Over the last decade or so, an array of new drugs has arrived. Drugs that promise real improvements for both type 1 and type 2 diabetes. None of them approaches a cure.
May
TII Diabetes Drug To Be Sold As Weight Loss Medication
Danish pharmaceutical company Novo Nordisk announced plans to re-brand and sell its diabetes drug liraglutide (Victoza) as a weight loss drug for obese people by 2015.
May
Diabetes Self-Management: Statin May Reduce Benefits of Exercise
The generic cholesterol-lowering drug simvastatin, previously sold under the brand name Zocor, may diminish the positive effects of exercise in overweight and obese adults
May
Diabetes Health – Two New Promising Type 2 Drugs in the Pipeline from Lilly
Both drugs are injectable glucagon-like peptides (amino acids) designed to be used once a week. The company is hoping to submit data from the studies to U.S. regulatory authorities this year seeking marketing approval for the new drug.
May
First Oral Insulin Drug Gains FDA Approval To Begin Testing
Those with diabetes know the everyday struggle to maintain blood sugar levels at that sweet spot between too high and too low. In order to test their blood glucose levels, diabetic patients have to prick their fingers often and take medication.
May
ScienceDaily: Newer Diabetes Medications May Have Additional Cardiovascular Benefits
A newer class of medications used to control blood sugar levels in type 2 diabetics may also improve cardiovascular health, researchers from The Ohio State University Wexner Medical Center reported
May
Diabetes Self-Management: Metformin May Delay Aging Process
The oral diabetes drug metformin may slow the aging process by mimicking the effects of a calorie-restricted diet, according to a new animal study from the United Kingdom.
May
Medical News Today – Saxagliptin/Metformin Combo: Added Benefit Not Proven for TII
The fixed combination of the drugs saxagliptin and metformin (Komboglyze®) has been approved in Germany since November 2011 for the treatment of type 2 diabetes mellitus.
May
Diabetes and Aspirin May Not Always Mix
While aspirin is often recommended to lower the risk of heart attack in those with diabetes, new research suggests that it may not always help, and it could do more harm than good.
Apr
Hormone Dramatically Increases Insulin Production, Possible Diabetes Breakthrough
A hormone, called betatrophin, that may significantly improve type 2 diabetes treatment has been discovered by scientists at the Harvard Stem Cell Institute (HSCI), according to a report published in Cell.
Apr
DiabetesInControl: SOGA, New Pill in the Works for Type 1 Patients
SOGA, a protein that lowers blood glucose, is missing in type 1 patients. SOGA is released when insulin is released and works by blocking the production of glycogen when food is being consumed.
Apr
The tablet of youth is coming
At TEDxSydney 2013 the Professor of Genetics at Harvard Medical School shares a new concept about why we age and how it should be possible to develop medicines to reverse it.
Apr
FDA reviewing heart risks of Glaxo diabetes pill Avandia
The Food and Drug Administration will hold a meeting in June to reassess the safety of GlaxoSmithKline’s former blockbuster diabetes drug Avandia.
Apr
Risk of new-onset diabetes varies with different statins
Different types and doses of statins seem to correlate with distinct risks of developing new-onset diabetes mellitus (DM).
Apr
Diabetes Mine: A New Pill for Type 1 Diabetes?
What if someone said that you — someone with type 1 diabetes — could take a pill and your insulin requirements would not only drop, but they might be eliminated completely?
Apr
NBC: The essential guide to diabetes drugs
There are several classes of drugs that are used to lower blood sugar, improve your body’s response to insulin or cause weight loss so your body can improve its ability to regulate insulin and sugar
Apr
Forbes: New Diabetes Drug Invokana Has Major Treatment – And Market – Potential
A new treatment option will soon be available to people with type 2 diabetes with the FDA’s approval on Friday of Invokana, a first-in-class medication to lower blood sugar.
Apr
Four Type 2 Diabetes Drugs Approved in 3 Months, Not Good Enough
Yet while adding new items to the expanding type 2 diabetes drugs arsenal has its positive side, it’s not good enough, and here’s why.
Mar
How Metformin Prevents Aging And Cancer Progression
University of Montreal researchers have discovered a novel molecular mechanism that can potentially slows the aging process and may prevent the progression of some cancers.
Mar
Novo Nordisk Creates Insulin Pill
Novo Nordisk, in conjunction with Danish manufacturer Merrion Pharmaceuticals Plc., have tested oral insulin and successfully completed early stages trials.
Mar
FDA approves new once-a-day diabetes drug
The Food and Drug Administration says it has approved a first-of-a-kind diabetes drug from Johnson & Johnson that uses a new method to lower blood sugar.
Mar
No More Needles: Insulin Pill Successful in Test
Novo Nordisk’s oral insulin successfully completed an early-stage study bringing what would be the first product of its kind a step closer to market.
Mar
Do Statin Medications Cause Diabetes or Raise Blood Sugar?
The current recommendation from both the Food and Drug Administration and the FDA and Health Canada, is that the benefits outweigh the risk for people who need to take statins.
Mar
7 Tips for Managing Diabetes Medications
Adhering to your diabetes medication schedule will mean fewer blood sugar ups and downs, but that’s often easier said than done. These ideas will help you stay on the clock.
Mar
FDA probes new pancreas risks with diabetes drugs (Update)
The U.S. Food and Drug Administration is looking into new evidence that suggests a group of recently approved diabetes drugs can increase the risk of pancreatitis and other problems.
Mar
Alogliptin effective for blood sugar control
Recently, scientists reviewed 10 studies that evaluated the use of medication alone or in combination with other antidiabetic drugs. Based on their review, investigators found alogliptin to be an effective therapy to control blood sugar levels.
Mar
Drug may ease angina in people with type 2 diabetes
The drug Ranexa (ranolazine) may help reduce chest pain in people with type 2 diabetes, a new study finds.
Mar
Diabetic medication may protect patients from developing heart failure
A class of medications commonly prescribed to lower blood sugar in diabetic patients appears to protect them from developing heart failure.
Mar
From Harvard University.. Anti-Aging Drug Breakthrough
Drugs that combat aging may be available within five years, following landmark work led by an Australian researcher.
Feb
Risk of pancreatitis doubles for those taking new class of diabetes drugs
People who take the newest class of diabetes drugs to control blood sugar are twice as likely as those on other forms of sugar-control medication to be hospitalized with pancreatitis, Johns Hopkins researchers report.
Feb
Pioglitazone approved by FDA for abbreviated new drug application
The FDA announced it has approved the abbreviated new drug application for pioglitazone, indicated for the treatment of type 2 diabetes in addition to diet and exercise.
Feb
Canker sore drug helps mice lose weight without diet, exercise
Doctors at the university will begin studies in human beings later this year. Hopes are high, even though many drugs that work in mice do not work in humans.
Feb
Old drug, Amlexanon, reverses obesity and diabetes in mice
Researchers at the University of Michigan’s Life Sciences Institute have found that amlexanox, an off-patent drug currently prescribed for the treatment of asthma and other uses, also reverses obesity, diabetes and fatty liver in mice.
Feb
Diabetes Self-Management: Drugs for Diabetes Pain
Pain researcher Rebecca Sudore, MD, says, “Adults living with Type 2 diabetes are suffering from incredibly high rates of pain, at levels similar to patients living with cancer.” Sounds awful. But what can we do about it? Actually, quite a bit.
Jan
FDA approves 3 new drugs for type 2 diabetes
All three drugs contain a new active ingredient, alogliptin, either alone or in combination with other, previously approved medications. The newly approved drugs include Nesina (alogliptin), Kazano (alogliptin plus metformin) and Oseni (alogliptin plus pioglitazone).
Jan
Biodel Ultra-Rapid Insulin Formulations Show Positive Results for TI
In a trial of 12 patients with Type 1 diabetes, Biodel’s two formulations showed significantly more rapid absorption rates and declines from peak concentrations. Discomfort levels associated with BIOD-250 were comparable to Humalog, though those related to BIOD-238 were significantly higher.
Jan
Novo Nordisk gets green light for Tresiba in Europe
Denmark’s Novo Nordisk, the world’s biggest insulin producer, said on Monday it got the final go-ahead from authorities to market its long-acting diabetes drug Tresiba in Europe.
Jan
DiabetesHealth. Metformin Bests Glipizide in Reducing Cardio Events
A Chinese research study of diabetes patients with coronary heart disease concludes that metformin is more effective than glipizide in reducing the risk of major cardiovascular events, such as stroke and heart attack.
Jan
Long Duration of Diabetes, Insulin Use, Ups Risk of Cancer
New research has found that people who have had diabetes for a long time are more likely to be diagnosed with cancer than those who have had it for a shorter time.
Jan
Obesity And Diabetes TII Treatment EndoBarrier® Enters U.S. Pivotal Clinical Trial
GI Dynamics, Inc. (ASX: GID) have announced that it has initiated its U.S. multicenter pivotal clinical trial of EndoBarrier®, the ENDO Trial, for the treatment of patients who have uncontrolled type 2 diabetes and are obese.
Jan
Type 2: Oramed Sends Oral Insulin Test Request to FDA
Israel-based Oramed announced that it has sent an application to the Food and Drug Administration for permission to enter Phase 2 trials of its oral insulin product.
Jan
Drugs for diabetes: Scientists test the power of plants
A group of researchers from the university’s School of Science, led by Dr Solomon Habtemariam, believe they have identified potential sources of medicines derived from plants which may have fewer adverse side-effects for diabetes sufferers.
Jan
GSK Announces Regulatory Submission Of Its Type 2 Diabetes Drug Albigultide
GlaxoSmithKline has announced a regulatory submission to the U.S. Food and Drug Administration for its type 2 diabetes drug called albigultide.
Jan
US panel backs novel diabetes pill from J&J (Update)
A panel of U.S. health experts ruled Thursday that an experimental diabetes drug from Johnson & Johnson is safe and effective, though lingering safety questions must be tracked over the long term.
Jan
Metformin cuts cardio events in high-risk type 2 diabetes
Metformin therapy significantly reduces cardiovascular events in high-risk patients with type 2 diabetes compared to treatment with glipizide, according to a study published online Dec. 10 in Diabetes Care.
Jan
FDA staff: J&J diabetes drug may pose heart risk
Federal drug reviewers think Johnson & Johnson’s experimental diabetes drug might bring heart risks because it raised cholesterol levels in patient testing.
Jan
Reuters: Lilly, Boehringer TII diabetes drug meets goals in trials
Eli Lilly and Co and Boehringer Ingelheim said on Monday that an experimental treatment for type 2 diabetes, empagliflozin, met the primary goal of significantly lowering blood sugar levels in four late-stage trials.
Jan
Study: Most-used diabetes drug works in different way than previously thought
Research in mice found that metformin suppresses the liver hormone glucagon’s ability to generate an important signaling molecule, pointing to new drug targets. The findings were published online this week in Nature.
Jan
Lucentis nears final NICE nod for diabetes-related vision loss
Novartis is one step closer to marketing Lucentis in a new group of patients. The National Institute for Health and Clinical Excellence officially changed its mind on the Swiss drugmaker’s eye treatment, recommending the pricey injection for use in diabetics.
Dec
EmaxHealth: Are cholesterol medications overprescribed for patients with type 2 diabetes?
Researchers from the VA Ann Arbor Healthcare System (VAAAHS) and the University of Michigan Health System highlight the importance of taking an individualized approach when it comes helping people with diabetes minimize their risks for heart disease.
Dec
DiabetesHealth: Metformin May Boost Cancer Survival, Curb Depression
Like aspirin, metformin is one of those drugs that over the years keeps proving itself beneficial in ways it wasn’t originally intended to be.
Dec
Imeglimin Beneficial As Add-On to Metformin in T2DM
For patients with type 2 diabetes inadequately controlled by metformin alone, addition of the new oral anti-diabetes agent imeglimin improves glycemic control with good tolerability and safety, according to a study published online Nov. 16 in Diabetes Care.
Dec
An explanation of diabetes incretin medications
In the last 10 years, new types of diabetes medications have resulted in improved diabetes control. Diabetes incretins are among those newer medications that are proving to be very effective. As you probably know, untreated Type 2 diabetes can be fatal.
Dec
New study shows Metmorfin is effective in treating very obese children
Treating obese children at risk for type 2 diabetes with the diabetes drug metformin was shown to be safe and effective.
Dec
Instrument Detects Sulfonylurea Levels in Diabetics
A major cause of hypoglycemia is excess sulfonylurea administration – taking a common medication without eating, or taking too much of it. Many, many trips to the emergency department arise from trouble with sylfonylurea meds.
Dec
New Type 2 diabetes drug promotes weight loss
A new drug for type 2 diabetes, involving research at Aston University is being launched as a once-daily tablet for adults with the condition.
Dec
A Long-Acting Form of Byetta for Treating TII Diabetes
The latest medication for people with type 2 diabetes is Bydureon, revealed early this year 2012.
Dec
Diabetes Self-Management: Drug Improves Vision in Diabetic Retinopathy
The eye drug Lucentis (ranibizumab injection), approved in August to treat diabetic macular edema, may also be useful in people with diabetic retinopathy, according to research
Nov
Common therapies reduce depression in diabetics, study finds
People living with diabetes may be able to reduce the risk of developing depression and other mood disorders by including a common medication in the management of their condition.
Nov
Research shows diabetes drug improves memory
An FDA-approved drug initially used to treat insulin resistance in diabetics has shown promise as a way to improve cognitive performance in some people with Alzheimer’s disease.
Nov
New insulin Degludec far better than existing insulins
This new insulin is far better than existing insulins available in the market both in terms of efficacy and safety. It is an ultra long acting drug with a half life of 25 hours.
Nov
US biopharma: 221 drugs now in R&D for diabetes, related conditions
They include 32 new treatments for type 1 diabetes, 130 for type 2, 14 for unspecified diabetes and 64 for diabetes-related conditions, says PhRMA, which describes this pipeline as “an exciting new chapter in the ongoing quest to better treat this debilitating disease.”
Nov
Metformin Tops Sulfonylureas for Heart Health
To compare the effects of metformin and sulfonylureas on cardiovascular outcomes such as heart attack, stroke, and death, researchers looked at the charts of more than 250,000 veterans receiving health care at Veterans Health Administration hospitals across the United States.
Nov
AstraZeneca’s FORXIGA™ Now Approved in European Union for Treatment of Type 2 Diabetes
FORXIGA is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2) that works independently of insulin to help remove excess glucose from the body, a unique mode of action not seen in any other currently available treatments.
Nov
Type 2 Diabetes and Beta-Blockers, What You Should Know
“Studies show that older beta- blockers can increase a patient’s risk of type 2 diabetes by more than 25 percent.” While raising the risk of diabetes is not good for anyone, it is especially damaging for individuals who already have conditions that affect the heart and vascular system.
Nov
FDA Panel Backs New Diabetes Drug
Yesterday, the FDA’s Endocrinologic & Metabolic Drug Advisory Committee voted to recommend approval for degludec, a new long acting insulin for the treatment of type 1 and type 2 diabetes.
Nov
Research: Popular diabetes meds put to the test
Patients with diabetes who were treated with the popular oral medication metformin face a lower risk of heart attack, stroke or death than those taking sulfonylureas, another common option, according to a large, multi-year study.
Nov
Head-to-head trial of two TII diabetes drugs yields mixed results
A direct, head-to-head comparison of two of the newer treatments available for type 2 diabetes yielded mixed results.
Nov
U.S News. Pharmacists’ Picks: Top Recommended Health Products
These pharmacist-recommended over-the-counter products will make your next trip to the drugstore easier. Scroll down to find recommendations for diabetics.
Nov
Lilly Says Its New Injectible Outperforms 3 Popular Diabetes Drugs
Lilly says its once-weekly injectible drug, dulaglutide, has outperformed three other widely taken diabetes drugs in three just-concluded Phase III studies.
Nov
Intravitreal insert provides substantial long-term benefit in DME patients
Fluocinolone acetonide intravitreal inserts substantially improved visual acuity for up to 3 years in patients with diabetic macular edema, according to the FAME studies.
Nov
New insulin analog shows promise
The novel basal insulin analog LY2605541 may show advantages over insulin glargine in diabetics, according to researchers.
Oct
Drug offers new pain management therapy for diabetics
A study from the University of Calgary’s Hotchkiss Brain Institute shows there is evidence to support a new drug therapy called nabilone to treat diabetic neuropathy, or nerve pain.
Oct
Generic Actos Receives Final Approval
Watson Pharmaceuticals Inc. said Friday that it began shipping a generic version of the type 2 diabetes treatment Actos.
Oct
ViaCyte gets funding for potential diabetes cure
ViaCyte is developing a drug delivery system that enables implanted pancreatic progenitor cells to survive and differentiate into functioning insulin-producing islet cells.
Oct
Insulin Degludec Beats Sitagliptin in Type 2 Diabetes
Adding insulin degludec to an existing oral antidiabetes regimen produced significantly better glycemic control than did adding sitagliptin in the first head-to-head trial of the two drug classes in patients with type 2 diabetes.
Oct
Lilly’s dulaglutide tops 3 diabetes drugs in late-stage trials
Eli Lilly & Co’s experimental once-weekly diabetes drug dulaglutide proved superior in late-stage clinical trials to three other widely used medicines that are dosed more frequently, the company said on Monday.
Oct
Oral Agents for Lowering Blood Sugar in Type 2 Diabetes
There are currently eight categories of oral agents marketed in the US for lowering blood sugar in type 2 diabetes. Each category has different reasons for use, differing efficacies for different individuals, etc.
Oct
Glucose Control Can Blunt Aspirin Resistance
Aspirin resistance – a concern among patients with type 2 diabetes who may be at high risk of heart disease – may be attenuated by aggressive glucose-lowering therapy, researchers said here.
Oct
Type 2: Finnish Study Says Statins Users Run Higher Diabetes Risk
Recently, a Finnish study evaluated nearly 2,800 nondiabetic individuals, close to 500 of whom were using statins, after they had participated in a year of lifestyle interventions intended to improve their glucose metabolism.
Oct
Use of more costly diabetes medications varies widely
Even within an integrated Veterans Affairs (VA) system with a uniform national formulary and established criteria for drug use, there is substantial variation in the use of thiazolidinediones and long-acting insulin.
Oct
Target for Obesity Drugs Comes Into Focus
Researchers at the University of Michigan have determined how the hormone leptin, an important regulator of metabolism and body weight, interacts with a key receptor in the brain.
Oct
Statins show raised blood glucose levels in new study
In a Finnish study of nearly 3,000 people at high risk of diabetes, those taking statins had higher fasting blood glucose and triglyceride levels and a higher incidence of developing type 2 diabetes than non-statins users.
Oct
Monoclonal antibody effective therapy for diabetic retinopathy
An antibody can reduce retinal vascular leakage and inflammation in rat models of diabetic retinopathy, according to a study published online Oct. 1 in Diabetes.
Oct
Merck’s once-a-week diabetes drug effective in clinical study
An experimental once-a-week drug for type 2 diabetes being developed by Merck & Co proved effective in lowering blood sugar levels in a mid-stage clinical trial, according to data presented on Wednesday.
Oct
New Data Demonstrate Treatment With ‘Januvia’ Works for Hypoglycemia
New data announced at the 48th European Association for the Study of Diabetes (EASD) annual meeting show results of post-hoc pooled analysis of patients with type 2 diabetes aged 65 or older.
Sep
Metformin May Be Useful for More People Than Previously Thought
Metformin is an oral medicine for Type 2 diabetes that belongs to a drug class known as biguanides. It helps lower blood glucose levels by making muscle and fat cells more sensitive to insulin.
Sep
New drug can reverse type II diabetes (Video)
A new drug has been developed which is capable of halting the progression of type II diabetes in animals and actually reversing the disease.
Sep
MedicalXpress: New drug candidate in diabetes research breakthrough
CSL Limited has developed a new drug candidate that is able to prevent the development of type 2 diabetes and reverse its progression in animal models of the disease.
Sep
Five-Cent Diabetes Pill From 1958 May Be New Cancer Drug
The next new treatment for breast, colon and prostate cancers, among others, may be a diabetes drug first approved in 1958.
Sep
Use diabetes drug with caution, says ministry
Avandia had been registered since July 2000, had closely monitored the drug following information on excess water retention and risk of heart failure and adverse cardiovascular effects connected to its consumption.
Sep
New York Man Alleges that Diabetes Medication Actos Caused Bladder Cancer
Actos is a type 2 diabetes medication that has been linked to bladder cancer in a number of studies. According to a recent report in Consumer Reports, the risks of taking Actos outweigh the benefits for most patients.
Sep
Research: More patients may benefit from effective antidiabetic drug
The antidiabetic drug metformin is not prescribed for patients with reduced kidney function because the risk of adverse effects has been regarded as unacceptably high.